Bioequivalence Analysis
The detailed pharmacokinetic parameters and the 90% CI for the ratio of the logarithmically transformed pharmacokinetic parameters are described in Table 3 . Based on the multivariate ANOVA no significant difference was found in both Cmax and AUC0-t between the test and reference formulations. It is shown that the 90% CIs were 91.40-107.57% for Cmax, 91.69-103.63% for AUC0-t, 92.27-104.37% for AUC0-∞. In addition, the GMRs for Cmaxand AUC were all within 0.80-1.25, and Tmax values were comparable between test and reference formulations under fasting or fed condition. The detailed results are shown in Table 3 . As indicated in Figure 4 , the individual difference of log Cmax and log AUC0-t values was in a narrow range for the T and T formulations. Therefore, the test formulation was considered bioequivalent to the reference formulation.
Table 3 Bioequivalence evaluation for the main pharmacokinetic parameters of gefitinib under fasting and fed conditions